Status:
COMPLETED
Microperimetric Evaluation After Half-dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy
Lead Sponsor:
Surugadai Nihon University Hospital
Collaborating Sponsors:
Teikyo University
Conditions:
Chronic Central Serous Chorioretinopathy
Eligibility:
All Genders
30-80 years
Phase:
NA
Brief Summary
A half-dose photodynamic therapy, a relative new treatment, has been widely performed to treat central serous chorioretinopathy. The researchers aimed to investigate whether the therapy improved the ...
Detailed Description
The best-corrected visual acuity (BCVA), macular sensitivity, and fixation stability were evaluated at the baseline and at 1, 3, 6, and 12 months after the half-dose photodynamic therapy. The macular ...
Eligibility Criteria
Inclusion
- the presence of subretinal fluid involving the fovea in the Optical coherence tomographic (OCT) images
- a serous retinal detachment of at least 6 months duration.
Exclusion
- evidence of a choroidal neovascularization (CNV), polypoidal choroidal vasculopathy, or other maculopathy documented by fluorescein angiography or Indocyanine green angiography
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2010
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT01434095
Start Date
October 1 2008
End Date
July 1 2010
Last Update
September 15 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Ophthalmology, Surugadai Nihon University Hospital
Chiyoda-ku, Tokyo, Japan, 101-8309